Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

PostScription: It Is Not Just What You Say…But How You Say It!

Author(s):  Reed-Kane Dana

Issue:  Jul/Aug 2008 - Hormone Replacement Therapy
View All Articles in Issue

Page(s):  375

PostScription: It Is Not Just What You Say…But How You Say It! Page 1

Download in electronic PDF format for $75

Abstract:  

Related Keywords: bioidentical hormone replacement therapy, communication, drug safety, patient education, U.S. Food and Drug Administration, FDA, estriol, BHRT

Related Categories: HRT, LEGAL, PROFESSIONAL ISSUES

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
PostScription: It Is Not Just What You Say…But How You Say It!
Reed-Kane Dana
Jul/Aug 2008
Pg. 375

Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
Jul/Aug 2020
Pg. 296-297

PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
Jul/Aug 2016
Pg. 351

View Sample
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Miller David G
Jul/Aug 2015
Pg. 303-305

The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Brunner Scott
Jan/Feb 2023
Pg. 22-23

U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
Nov/Dec 2015
Pg. 487-488

U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)
Nov/Dec 2016
Pg. 457-458

Menopausal Women's Access Path to Bioidentical Hormone Replacement Therapy: An Exploratory Study
Moro Doris
, Young Wendy, Stein Richard, Isaac Winston, Goodman Deborah
Mar/Apr 2010
Pg. 165-170

Efficacy and Tolerability of Compounded Bioidentical Hormone Replacement Therapy
Vigesaa Kristy A
, Downhour Nathan P, Chui Michelle A, Cappellini Linda, Musil John D, McCallian Dennis J
Jul/Aug 2004
Pg. 313-319

The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States
Stephenson Kenna
, Jones William, Stephenson Douglas M M
May/Jun 2006
Pg. 175-183

U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Snow Stephen T
, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Jan/Feb 2019
Pg. 32-33

U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Yoch Doug
Mar/Apr 2017
Pg. 95-102

The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Miller David G
May/Jun 2014
Pg. 208

Hormone Therapy: It's Time for a Second Opinion
Collins Joseph J
, Ahlgrimm Maria
Mar/Apr 2008
Pg. 122-127

Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration
Kupiec Tom
, Kemp Jesse
Jul/Aug 2007
Pg. 326-327

Menopausal Symptom Relief and Side Effects Experienced by Women Using Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 1
Deleruyelle Laura J
Sep/Oct 2016
Pg. 359-364

Guidelines for Consulting with Patients about Bioidentical Hormone Replacement Therapy
White Irene Q
Jul/Aug 2005
Pg. 266

Bioidentical Hormone Replacement Therapy, Part 2, A Review of
Wepfer Scott T
Jan/Feb 2002
Pg. 50-54

PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 1
Allen Loyd V Jr
Jul/Aug 2007
Pg. 350-351

Return to Top